Schizophrenia and Psychotic Disorders

Home > Schizophrenia Psychiatrist NYC

Scope — read this first

I practice in an outpatient private setting in Chelsea. That is the right environment for:

• Diagnostic clarification and second opinions
• Antipsychotic optimization, including switching and dose reduction
• Clozapine initiation and management for treatment-resistant illness
• Long-acting injectable management
• Medical monitoring — metabolic, movement disorder, ANC
• Ongoing outpatient care for someone stable

It is not the right setting for acute psychosis requiring hospitalization, first-episode psychosis needing coordinated specialty care, or assertive community treatment. If that's what's needed I will say so and help find it — first-episode programs in particular produce meaningfully better outcomes than general outpatient care, and getting someone into one is worth more than treating them here.

In crisis: call or text 988, or go to the nearest emergency department.

The clozapine problem

This is my published area.

Clozapine is the only antipsychotic with established efficacy in treatment-resistant schizophrenia — inadequate response to two adequate trials of other antipsychotics. It is also the only antipsychotic shown to reduce suicidality in this population.

And it is dramatically underused. US prescribing rates run around 4–5% of patients with schizophrenia, against an estimated 20–30% who would meet treatment-resistance criteria. Hundreds of thousands of people are on medications that aren't working while the one that might is never offered.

This is not speculation about the monitoring burden — my lab measured it. When the FDA relaxed clozapine blood-count monitoring requirements in 2015, we evaluated the consequences using de-identified Veterans Affairs electronic health record data. The less restrictive guidelines did not increase agranulocytosis cases, and appeared to increase clozapine prescribing. (Columbia lab page)

That is the empirical answer to the most common objection: the monitoring that keeps clozapine underused was relaxed, and safety did not deteriorate. The 2024 REMS changes went further still.

The remaining barriers are well characterized and mostly not clinical:

• ANC monitoring requirements. Weekly initially, then less frequent. Genuinely burdensome, and manageable — see the finding above.
• Prescriber unfamiliarity. Many psychiatrists complete training having never initiated clozapine.
• Overstated risk perception. Agranulocytosis is serious and monitorable. Myocarditis is rare and detectable. Untreated treatment-resistant schizophrenia is not a safe alternative.
• Demographic disparities in who gets offered it, which is what my research documented.

If you or a family member has failed two antipsychotics and clozapine has never been discussed, that is a conversation worth having.

Diagnosis

Duration of untreated psychosis is one of the more robust predictors of long-term outcome, which makes accurate early diagnosis genuinely consequential.

What warrants careful differentiation:

• Substance-induced psychosis — stimulants, high-potency cannabis, hallucinogens. My NIDA-funded research concerns adolescent cannabis and psychosis risk; daily high-potency use carries substantially elevated risk.
• Bipolar disorder with psychotic features — different treatment, different course.
• Depression with psychotic features — responds to combined antipsychotic and antidepressant treatment, or to ECT.
• OCD with poor insight — obsessions occasionally mistaken for delusions. The treatments have nothing in common.
• Medical causes — autoimmune encephalitis, temporal lobe epilepsy, delirium, thyroid disease.

Treatment

Antipsychotics are foundational. Selection is driven by side effect profile more than efficacy, since apart from clozapine the agents perform comparably. Metabolic effects, movement disorders, sedation, and prolactin elevation differ substantially and determine whether someone stays on treatment.

Long-acting injectables deserve more consideration than they get. They remove the daily adherence question entirely and are associated with lower relapse rates. They are frequently framed as a last resort; often they are the better first choice.

Monitoring is treatment. Metabolic parameters, movement disorder screening, and prolactin. Antipsychotics carry real long-term risks and someone has to be watching for them.

Psychosocial treatment. CBT for psychosis has real evidence as an adjunct. Family psychoeducation reduces relapse. Supported employment works. None substitute for medication.

For families

You may be the one reading this. What I can offer: a clear diagnostic assessment, an honest account of what the medications do and cost, a direct answer on whether clozapine should be on the table, and a straight answer about whether this practice is the right setting or whether a hospital-based program would serve better.

Related

Bipolar · Medication management · Cannabis and substance use · Second opinions · Cannabis research

When Psychosis Becomes an Emergency

Acute psychosis requires hospital-level evaluation that outpatient care cannot provide. Go to the nearest emergency department — a first psychotic episode in particular should be evaluated the same day.

Frequently Asked Questions

What is treatment-resistant schizophrenia?

Inadequate response to two adequate trials of antipsychotic medication — meaning therapeutic doses for sufficient duration. An estimated 20 to 30 percent of people with schizophrenia meet this definition.

Why isn't clozapine prescribed more often?

Documented barriers include neutrophil monitoring requirements, prescriber unfamiliarity, overstated risk perception, and demographic disparities in who is offered it. US prescribing rates run around 4 to 5 percent against an eligible population several times larger.

Is clozapine dangerous?

It carries real risks — agranulocytosis and myocarditis among them — which is why monitoring exists. Those risks are detectable and manageable. Untreated treatment-resistant schizophrenia is not a safer alternative, and clozapine is the only antipsychotic shown to reduce suicidality in this population.

Can cannabis cause schizophrenia?

Daily high-potency cannabis use is associated with substantially elevated psychosis risk, particularly with adolescent onset. Whether it causes schizophrenia in someone who would otherwise never develop it remains debated; that it precipitates and worsens psychosis in vulnerable people is well supported.

Do you treat first-episode psychosis?

First-episode psychosis is best served by coordinated specialty care programs, which produce better outcomes than general outpatient treatment. I will say so and help arrange a referral rather than treat it here.

Are long-acting injectables better than pills?

They remove the daily adherence question and are associated with lower relapse rates. They are often framed as a last resort when for many patients they are a reasonable first choice.